NTCA Provider Guidance: Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI)
HTML: http://www.tbcontrollers.org/resources/tb-infection/3hp/#.X6MDL6-P6Hk
Abstract
The resource was designed to help healthcare providers:
1. Quickly identify and answer key questions when considering whether to start a patient on the isoniazid-rifapentine (3HP) regimen
2. Assess the appropriateness of self-administered therapy of 3HP for each individual patient
3. Ensure that the correct drugs for the 3HP regimen are prescribed and provided to the patient
4. Handle questions on side effects and adverse reactions for a patient currently on the 3HP regimen
Publisher:
National Tuberculosis Controllers Association
Audience(s):
Health Professionals, Physicians
Topic:
Diagnosis, TB Treatment, Treatment - Latent TB infection (Inactive TB), Treatment- Medication Information
Notes:
The material supplements CDC's guidance, Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection, MMWR, June 29, 2018;67(25):723–726.